English 
لا توجد منتجات في سلة المشتريات.
CEREBROLYSIN 10 AMP 1 ML
220.00 EGP
متوفر في المخزون
| * To be used only under medical supervision. | ||
| * Manufactured by: GlaxoSmithKline S.A.E. – A.R.E. | ||
| * Cerebrolysin 1ml – 10 ampoules of 1 ml. Solution for injection / concentrate for solution for infusion. | ||
| * Administration: Intramuscular (I.M.) or I.V. (intravenous) use. | ||
| * Active ingredient: 1ml contains: 215.2mg of Cerebrolysin concentrate in aqueous solution. Excipients: Sodium hydroxide, water for injection. | ||
| * For the modern, safe and effective treatment of disturbed cerebral functions. | ||
| * Indications: | ||
| – Disturbances of concentration && memory. | ||
| – Degenerative dementias, including Alzheimer’s disease. | ||
| – Vascular dementias, e.g. multi-infarct dementia. | ||
| – Mixed forms of dementia (degenerative && vascular contribution). | ||
| – Sequels of stroke (ischaemic && haemorrhagic). | ||
| – Posttraumatic or postoperative complaints e.g., following cerebral contusion, concussion, or neurosurgical operation. | ||
| * Contra-indications: | ||
| – Status epilepticus or grand mal convulsions; an increase in the seizure frequency may be seen in these cases. | ||
| – Severe impairment of renal function. | ||
| * Warnings and precautionary measures: | ||
| & Patients with severe renal impairment must be excluded from a Cerebrolysin therapy. Animal experimental data did | ||
| & not show any evidence of teratogenic effects. There is no clinical experience with Cerebrolysin in pregnant women. | ||
| & Therefore, unless the potential benefits outweigh any potential risk, Cerebrolysin should not be administered during | ||
| & pregnancy and the lactation period. | ||
| * Interactions: Concomitant administration of Cerebrolysin with antidepressive drugs or MAO inhibitors can lead to cumulative effects. | ||
| & In these cases a dose reduction of the antidepressive drug is advisable. | ||
| * Dosage: Cerebrolysin is available in 1mL, 5mL and 10mL ampoules and in vials of 30mL and 50mL. Up to 5mL per | ||
| & intramuscular administration, for administrations over 5mL an intravenous injection or infusion is advised. | ||
| & Cerebrolysin can also be given diluted in a standard IV solution (eg. physiological saline solution, Ringer’s | ||
| & solution, glucose 5%, dextran 40) infused slowly over approximately 20 to 60 minutes. Once daily applications | ||
| & of Cerebrolysin for a minimum of 10 to 20 days are recommended. This constitutes a course of therapy. | ||
| & In mild cases 1-5mL, in severe cases 10-30mL should be applied. The length of the therapy and the individual | ||
| & doses depends on the age of the patient as well as on the severity of the disease. Usually a treatment period | ||
| & of 3 to 4 weeks is recommended. Therapy courses can be repeated several times in accordance with the | ||
| & clinical picture of the patient until no further improvement can be observed. Therapy-free intervals should be | ||
| & maintained between courses. In severe cases it is advisable not to interrupt treatment abruptly but to continue | ||
CEREBROLYSIN (PORCINE BRAIN EXT) 215.2 MG / 1 ML - (FOR I.M. / I.V. USE) منتجات ذات صلة
الأدوية المضادة لتجلط الدم
515.00 EGP
الأدوية المضادة لتجلط الدم
145.00 EGP
الأدوية المضادة لتجلط الدم
274.50 EGP
الأدوية المضادة لتجلط الدم
165.00 EGP
|